Insider Selling: Natera (NASDAQ:NTRA) CEO Sells $790,079.00 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,950 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $200.02, for a total value of $790,079.00. Following the sale, the chief executive officer directly owned 156,607 shares of the company’s stock, valued at $31,324,532.14. This represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, February 3rd, Steven Leonard Chapman sold 4,725 shares of Natera stock. The stock was sold at an average price of $230.77, for a total transaction of $1,090,388.25.
• On Monday, February 2nd, Steven Leonard Chapman sold 85,299 shares of Natera stock. The shares were sold at an average price of $230.72, for a total transaction of $19,680,185.28.
• On Wednesday, January 28th, Steven Leonard Chapman sold 3,648 shares of Natera stock. The shares were sold at an average price of $237.66, for a total transaction of $866,983.68.
• On Tuesday, January 27th, Steven Leonard Chapman sold 2,322 shares of Natera stock. The stock was sold at an average price of $240.53, for a total transaction of $558,510.66.
• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $373,650.00.
• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The shares were sold at an average price of $234.74, for a total value of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The stock was sold at an average price of $229.08, for a total value of $881,499.84.

Natera Stock Down 2.9%

Shares of Natera stock opened at $197.14 on Friday. The business has a fifty day simple moving average of $223.82 and a 200 day simple moving average of $204.71. The stock has a market cap of $27.94 billion, a PE ratio of -128.85 and a beta of 1.65. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $256.36.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. The firm had revenue of $665.50 million for the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.During the same quarter last year, the business earned ($0.41) earnings per share. Analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on NTRA shares. Guggenheim upped their target price on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. Piper Sandler lifted their target price on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Stephens increased their price target on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Finally, Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $253.47.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Reflection Asset Management acquired a new stake in Natera in the fourth quarter valued at $29,000. Palladiem LLC acquired a new position in shares of Natera during the 4th quarter worth about $31,000. Horizon Investments LLC bought a new stake in shares of Natera in the 3rd quarter valued at about $32,000. Bank of Jackson Hole Trust lifted its stake in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 83 shares during the last quarter. Finally, Sound Income Strategies LLC grew its holdings in Natera by 95.7% during the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after purchasing an additional 110 shares during the period. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.